MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B

 MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B

MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B

Shots:

  • MorphoSys to acquire all of the outstanding shares of Constellation’s common stock for $34.00/ share in cash making a total equity value of $1.7B. The transaction is expected to close in Q3’21
  • The acquisition will bolster Morphosys’ position in hematology-oncology & accelerates growth strategy with the addition of Constellation’s Pelabresib (CPI-0610) & CPI-0209
  • Additionally, MorphoSys enters into a strategic funding partnership with Royalty Pharma, under which MorphoSys will receive $1.425B as up front, $350M as development funding bonds, $150 as milestones. Royalty Pharma will receive royalties and is expected to invest $100M in a cash capital increase of MorphoSys

Click here to­ read full press release/ article | Ref: Businesswire | Image: Constellation Pharmaceuticals

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post